After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

WHAT TO WATCH --GSK has guided for full-year sales to grow between 3% and 5% and its core operating profit to increase between 6% and 8% excluding currency movements.

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and inflammation.

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week. GlaxoSmithKline, also known as GSK, is moving manufacturing operations ...

Manufacturing GSK telegraphs 150 layoffs amid plan to transfer vaccine manufacturing from Massachusetts site By Fraiser Kansteiner Jul 22, 2025 8:53am GSK drug manufacturing vaccine manufacturing ...

Under his leadership, iTeos raised over $1 billion in capital, completed a successful IPO, and secured a landmark $2 billion partnership with GSK to co-develop and commercialize the company’s lead ...

iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right ...